Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developin… Read more
Candel Therapeutics Inc (CADL) - Net Assets
Latest net assets as of September 2025: $80.12 Million USD
Based on the latest financial reports, Candel Therapeutics Inc (CADL) has net assets worth $80.12 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($93.60 Million) and total liabilities ($13.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $80.12 Million |
| % of Total Assets | 85.6% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 222.35 |
Candel Therapeutics Inc - Net Assets Trend (2019–2024)
This chart illustrates how Candel Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Candel Therapeutics Inc (2019–2024)
The table below shows the annual net assets of Candel Therapeutics Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $66.33 Million | +420.42% |
| 2023-12-31 | $12.74 Million | -73.29% |
| 2022-12-31 | $47.71 Million | -25.61% |
| 2021-12-31 | $64.14 Million | +372.21% |
| 2020-12-31 | $-23.56 Million | -193.13% |
| 2019-12-31 | $-8.04 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Candel Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 16571400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $469.00K | 0.71% |
| Other Components | $258.06 Million | 389.08% |
| Total Equity | $66.33 Million | 100.00% |
Candel Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Candel Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Egis Technology
TWO:6462
|
$245.37 Million |
|
EH3
F:EH3
|
$245.45 Million |
|
WAAREE RENEWABLE TECHNOLOGIES LTD
NSE:WAAREERTL
|
$245.45 Million |
|
Zhejiang Dilong New Material Co Ltd
SHE:002247
|
$245.48 Million |
|
PetroTal Corp
OTCQX:PTALF
|
$245.14 Million |
|
SYLVANIA PLAT. DL 001
F:31L
|
$245.13 Million |
|
Sichuan Qiaoyuan Gas Co.Ltd
SHE:301286
|
$245.07 Million |
|
Evolent Health Inc
NYSE:EVH
|
$244.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Candel Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,745,000 to 66,327,000, a change of 53,582,000 (420.4%).
- Net loss of 55,177,000 reduced equity.
- New share issuances of 101,758,000 increased equity.
- Other factors increased equity by 7,001,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-55.18 Million | -83.19% |
| Share Issuances | $101.76 Million | +153.42% |
| Other Changes | $7.00 Million | +10.56% |
| Total Change | $- | 420.42% |
Book Value vs Market Value Analysis
This analysis compares Candel Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.47x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.43 | $5.17 | x |
| 2020-12-31 | $-1.26 | $5.17 | x |
| 2021-12-31 | $2.24 | $5.17 | x |
| 2022-12-31 | $1.66 | $5.17 | x |
| 2023-12-31 | $0.44 | $5.17 | x |
| 2024-12-31 | $2.09 | $5.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Candel Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -83.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.61x
- Recent ROE (-83.19%) is below the historical average (-79.43%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -6592.00% | 0.00x | 0.00x | $-7.44 Million |
| 2020 | 0.00% | -14144.00% | 0.00x | 0.00x | $-15.32 Million |
| 2021 | -56.32% | -28899.20% | 0.00x | 1.39x | $-42.54 Million |
| 2022 | -39.39% | -15035.20% | 0.00x | 1.65x | $-23.57 Million |
| 2023 | -297.68% | -122383.87% | 0.00x | 3.23x | $-39.21 Million |
| 2024 | -83.19% | 0.00% | 0.00x | 1.61x | $-61.81 Million |
Industry Comparison
This section compares Candel Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Candel Therapeutics Inc (CADL) | $80.12 Million | 0.00% | 0.17x | $245.32 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |